Hoth Therapeutics Inc., a biopharmaceutical company specializing in treatments for rare and inflammatory diseases, has announced positive preclinical safety data for its investigational oncology candidate, HT-KIT. The study results, which have already been presented, demonstrated a dose-dependent increase in liver mass without any observed toxicity or adverse effects on other organs such as the kidney, spleen, and thymus. The findings support the safety profile of HT-KIT, with no visible lesions or gross pathology noted in treated animals. Hoth Therapeutics plans to proceed with GLP toxicology studies and aims to submit an Investigational New Drug $(IND.AU)$ application, marking a key step toward future clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.